Faisal, Farzana A.
Kaur, Harsimar B.
Tosoian, Jeffrey J.
Tomlins, Scott A.
Schaeffer, Edward M.
Lotan, Tamara L.
Funding for this research was provided by:
U.S. Department of Defense (PC141474, PC141474, PC141474)
Article History
Received: 7 November 2018
Revised: 5 January 2019
Accepted: 7 January 2019
First Online: 8 March 2019
Compliance with ethical standards
:
: SAT has received travel support from and had a sponsored research agreement with Compendia Bioscience/Life Technologies/Thermo Fisher Scientific, which assisted in the design of the custom RNAseq panel. The University of Michigan has been issued patents on ETS gene fusions in prostate cancer, on which SAT is a coinventor. The diagnostic field of use was licensed to Hologic/Gen-Probe Inc., which has sublicensed rights to Roche/Ventana Medical Systems. SAT has served as a consultant for and received honoraria from Janssen, AbbVie, Sanofi, Almac Diagnostics, and Astellas/Medivation. SAT has sponsored research agreements with Astellas/Medivation and GenomeDX. SAT is an equity holder in and employee of Strata Oncology. TLL has received research funding from Roche/Ventana Medical Systems for other projects and has served as a consultant for and received an honorarium from Janssen. The remaining authors declare that they have no conflict of interest.